Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon Seeks Partner For Silenor Insomnia Drug Switch

This article was originally published in The Tan Sheet

Executive Summary

P&G’s exit from the switch picture adds “salt to a wound left by” Somaxon’s unsuccessful prescription Silenor launch in 2010, Jeffries analysts note. Somaxon recently laid off 75% of its sales staff and drastically cut marketing to minimize its cash burn rate, which far outpaced initial sales.

You may also be interested in...



In Brief

Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.

Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market

Prestige Brands acquires GlaxoSmithKline’s BC and Goody’s analgesic brands as part of $660 million deal for 17 North American OTC lines, also including Beano gas treatment, FiberChoice supplement and Sominex sleep aid.

Somaxon Could Seek Buyer For Silenor Sleep Aid, OTC Marketing Rights

Somaxon reconsiders its options and might sell the sleep aid Silenor, despite a “clear path” to switch OTC, after the firm’s stock fell from $10.60 per share to 42 cents per share. Procter & Gamble would have first crack at exclusive OTC marketing rights if Somaxon sells Silenor.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel